Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial


Park K., ÖZGÜROĞLU M., Vansteenkiste J., Spigel D., Yang J. C. H. , Ishii H., ...More

JOURNAL OF THORACIC ONCOLOGY, vol.16, no.8, pp.1369-1378, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 8
  • Publication Date: 2021
  • Doi Number: 10.1016/j.jtho.2021.03.009
  • Title of Journal : JOURNAL OF THORACIC ONCOLOGY
  • Page Numbers: pp.1369-1378
  • Keywords: Avelumab, PD-L1, Non-small cell lung cancer, Second-line, Phase 3, OPEN-LABEL, NIVOLUMAB, MULTICENTER

Abstract

Introduction: In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.